Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

Virpax Pharmaceuticals, Inc.

Received Nasdaq notice on Dec 22, 2022 for non-compliance with minimum $1.00 bid price rule.
Closing bid price below $1.00 for last 30 consecutive business days triggered the notice.
Compliance deadline is June 20, 2023; must close at $1.00+ for 10 consecutive days.
Eligible for additional 180-day cure period if meeting other listing requirements and pursuing reverse split.
Company is evaluating options to regain compliance; no immediate delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Virpax Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 22, 2022, Virpax Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid p

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-22-083558

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.